NCT02187029View on ClinicalTrials.gov

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Gout
Interventions
DRUG

PF-06743649

Daily dosing (dose level 1) tablet for 14 days

OTHER

Placebo

Daily dosing (tablet) for 14 days

DRUG

PF-06743649

Daily dosing (dose level 2) tablet(s) for 14 days

OTHER

Placebo

Daily dosing (tablets) for 14 days

Trial Locations (4)

33143

MRA Clinical Research, LLC, Miami

Miami Research Associates, Inc., South Miami

66211

Vince and Associates Clinical Research Inc., Overland Park

66212

Vince and Associates Clinical Research, Inc., Overland Park

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02187029 - Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects. | Biotech Hunter | Biotech Hunter